Présentations scientifiques

Updated Results of the Phase I BALLI-01 Trial of UCART22, an Anti-CD22 Allogeneic CAR T-cell Product, in Patients with Relapsed or Refractory (R/R) CD22+ B-Cell Acute Lymphoblastic Leukemia (B-ALL) - EHA 2023 - Présentation Poster

Télécharger le PDF

UCART20x22: allogeneic dual CAR T-cells for the treatment of B-cell malignancies - ISCT 2023 - Présentation orale

Télécharger le PDF

Comprehensive Analysis of the Editing Window of TALE Base Editors - ISCT 2023 - Présentation poster

Télécharger le PDF

Non-viral DNA delivery associated to TALEN® gene editing leads to highly efficient correction of sickle cell mutation in long-term repopulating hematopoietic stem cells  - ISCT 2023 - Présentation poster

Télécharger le PDF

Expanding the Scope of Multiplex Engineering for Superior Generation of Efficient CAR T-cells - ASGCT 2023 - Présentation Poster

Télécharger le PDF

AMELI 01: A Phase I Trial of UCART123v1.2, an Anti CD123 Allogeneic CAR T Cell Product, in Adult Patients with Relapsed or Refractory (R/R) CD123+ Acute Myeloid Leukemia - ASGCT 2023 - Présentation orale

Télécharger le PDF

Deciphering the benefits of variable delivery routes and molecular armoring to enhance efficacy of MUC1-CAR T-cells in targeting triple-negative breast cancer - AACR 2023 - Présentation poster

Télécharger le PDF

AMELI-01:Preliminary Results from A Phase I Trial of UCART123v1.2, an Anti-CD123 Allogeneic CAR-T Cell Product, in Adult Patients with Relapsed or Refractory (R/R) CD123+ Acute Myeloid Leukemia - ASH 2022 - Présentation orale

Télécharger le PDF

Preclinical Activity of Allogeneic CS1-Specific CAR T-Cells (UCARTCS1) in Multiple Myeloma - ASH 2022 - Présentation poster

Télécharger le PDF

UCART20x22: First allogeneic dual CAR T-cell therapy for the treatment of B-cell malignancies - AACR 2022 - Abstract

Télécharger le PDF